ANTONARELLI, GABRIELE
ANTONARELLI, GABRIELE
Universita' degli Studi di MILANO
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study
2026 C. Valenza, J.D. Etessami, M. Milano, N. Papadopoulos, M. Alvino, G. Antonarelli, N. Bianco, C. Sangalli, D. Trapani, G. Pravettoni, E. Omodeo Salè, R. Passerini, M. Colleoni, E. Munzone, G. Curigliano
Real-world safety and efficacy profiles of trastuzumab deruxtecan in patients with advanced breast cancer
2025 G. Antonarelli, M. Milano, C. Andreon, S. Gandini, G. Pellizzari, D. Trapani, S. Dellapasqua, A. Marra, P. Zagami, C. Valenza, M. Colleoni, E. Munzone, G. Curigliano
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano
Redefining clinical trial strategic design to support drug approval in medical oncology
2025 G. Antonarelli, J.M. Pérez-García, M. Gion, H. Rugo, P. Schmid, A. Bardia, S. Hurvitz, N. Harbeck, S.M. Tolaney, G. Curigliano, A. Llombart-Cussac, J. Cortés
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
2024 C. Valenza, D. Trapani, P. Zagami, G. Antonarelli, L. Boscolo Bielo, E. Nicolò, J.M. Ribeiro, L. Guidi, C. Reduzzi, M. Spotti, L. Adamoli, J. Cortès, B. Pistilli, S.M. Tolaney, N. Ueno, R.M. Layman, M. Cristofanilli, L.A. Carey, E. Munzone, C. Criscitiello, F. Lynce, W.A. Woodward, G. Curigliano
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
2023 G. Antonarelli, B. Taurelli Salimbeni, A. Marra, A. Esposito, M.A. Locatelli, D. Trapani, C. Pescia, N. Fusco, G. Curigliano, C. Criscitiello
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
2023 G. Antonarelli, V. Pieri, F.M. Porta, N. Fusco, G. Finocchiaro, G. Curigliano, C. Criscitiello
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
2023 G. Antonarelli, C. Corti, P. Tarantino, B.T. Salimbeni, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents
2023 E. Nicolò, P. Tarantino, O. D'Ecclesiis, G. Antonarelli, L. Boscolo Bielo, A. Marra, S. Gandini, E. Crimini, F. Giugliano, P. Zagami, C. Corti, D. Trapani, S. Morganti, C. Criscitiello, M. Locatelli, C. Belli, A. Esposito, I. Minchella, M. Cristofanilli, S.M. Tolaney, G. Curigliano
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers
2023 P. Zagami, A. Comandone, M. Fiore, G. Giulio Baldi, G. Grignani, B. Vincenzi, A. Gronchi, G. Antonarelli, A. Boglione, E. Pennacchioli, G. Curigliano, F. Conforti, T.M. De Pas
Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe?
2022 C. Corti, G. Antonarelli, C. Valenza, E. Nicolò, H. Rugo, J. Cortés, N. Harbeck, L.A. Carey, C. Criscitiello, G. Curigliano
Targeting brain metastases in breast cancer
2022 C. Corti, G. Antonarelli, C. Criscitiello, N.U. Lin, L.A. Carey, J. Cortes, P. Poortmans, G. Curigliano
The Immune-related adverse event (IRAE) Likelihood Score (ILS) identifies “pure” IRAEs strongly associated with outcome in a phase I-II trial population
2022 L. Mazzarella, E. Nicolò, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. Trillo Aliaga, C. Valenza, M. Repetto, G. Antonarelli, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano
Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development
2022 P. Tarantino, G. Antonarelli, L. Ascione, G. Curigliano
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group
2022 G. Antonarelli, C. Corti, P.A. Zucali, M. Perrino, S. Manglaviti, G. Lo Russo, G.M. Varano, P. Salvini, G. Curigliano, C. Catania, F. Conforti, T. De Pas
Harmonizing PD-L1 testing in metastatic triple negative breast cancer
2022 F. Giugliano, G. Antonarelli, P. Tarantino, J. Cortes, H.S. Rugo, G. Curigliano
Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
2022 G. Antonarelli, C. Valenza, E.L. Mayer, S. Loibl, G. Curigliano
Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
2022 E. Crimini, M. Repetto, P. Tarantino, L. Ascione, G. Antonarelli, E.G. Rocco, M. Barberis, L. Mazzarella, G. Curigliano